Argenx price target raised to $607 from $535 at BofA

BofA raised the firm’s price target on Argenx to $607 from $535 and keeps a Buy rating on the shares after Vyvgart Hytrulo was approved in chronic inflammatory demyelinating polyneuropathy, or CIDP, with what the firm describes as “a broad, unrestricted label.” The firm, which says it is “highly encouraged by the large commercial opportunity in CIDP,” now models $4.2B in risk-adjusted peak sales, up from a previous peak forecast of $3.2B.